FUNDED INVESTIGATORS

Josep Llovet, M.D.
Mount Sinai School of Medicine

 Hepatocellular carcinoma (HCC) is a primary cancer of the liver whose treatment and prognosis options depend on tumor size and staging. HCC is the third leading cause of cancer-related deaths worldwide with the majority of the cases arising from chronic liver injury due to hepatitis B virus or hepatitis C virus infection.

Dr. Llovet is attempting to develop a classification system of HCC that is capable of predicting the cancer's recurrence and survival. He is also looking into identifying the genes and pathways that lead to the development of poor prognosis HCC using advanced technologies of genome and transcriptome sequencing, microRNA expression, copy number variation, and epigenetic changes.